Genmab receives patent for HuMax-HepC

By Angela McDaniels

Seattle, Nov. 3 - Genmab AS said that the U.S. Patent and Trademark Office has issued a patent for the company's HuMax-HepC antibody.

HuMax-HepC is in pre-clinical development and is intended to prevent reinfection with the Hepatitis C virus after liver transplantation.

"The patent provides broad protection over this unique antibody and gives us a potential edge over other biotech companies competing in the same arena," said Lisa N. Drakeman, chief executive officer of Genmab.

Genmab AS is a biotechnology company based in Copenhagen that creates and develops human

antibodies for the treatment of life-threatening and debilitating diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.